Emergent Biosolutions
(EBS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 231,100 | 140,900 | 222,200 | 194,700 | 293,800 |
| Cost of Goods | 85,900 | 66,900 | 88,500 | 118,000 | 122,600 |
| Gross Profit | 145,200 | 74,000 | 133,700 | 76,700 | 171,200 |
| Operating Expenses | 69,600 | 73,300 | 84,300 | 86,200 | 107,300 |
| Operating Income | 76,500 | 1,600 | 49,900 | -9,500 | 64,500 |
| Interest Expense | 15,200 | 14,700 | 14,700 | 14,800 | 8,300 |
| Other Income | -3,700 | -3,700 | 57,500 | -3,300 | 86,200 |
| Pre-tax Income | 57,600 | -16,800 | 92,700 | -27,600 | 142,400 |
| Income Tax | 6,400 | -4,800 | 24,700 | 3,700 | 27,600 |
| Net Income Continuous | 51,200 | -12,000 | 68,000 | -31,300 | 114,800 |
| Net Income | $51,200 | $-12,000 | $68,000 | $-31,300 | $114,800 |
| EPS Basic Total Ops | 0.96 | -0.22 | 1.25 | -0.55 | 2.16 |
| EPS Basic Continuous Ops | 0.96 | -0.22 | 1.25 | -0.55 | 2.16 |
| EPS Diluted Total Ops | 0.91 | -0.22 | 1.19 | -0.45 | 2.06 |
| EPS Diluted Continuous Ops | 0.91 | -0.22 | 1.19 | -0.45 | 2.06 |
| EPS Diluted Before Non-Recurring Items | 1.06 | 0.16 | 0.71 | 0.05 | 1.37 |
| EBITDA(a) | $102,400 | $27,500 | $77,600 | $18,700 | $84,200 |